EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on
approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates - PMC Back …

Precision medicine is essential for the modern care of a patient with cancer. Comprehensive
molecular profiling of the tumor itself is necessary to determine the presence or absence of …

Introduction Patients with life-threatening advanced non-small cell lung cancer (NSCLC)
who harbor an exon 20 deletion and/or insertion mutation (EGFRex20+) have limited …

Simple Summary The presence of an EGFR activating mutation in tumors of non-small-cell
lung cancer patients enables effective targeted therapy towards EGFR. Studies that describe …

Background: Tyrosine kinase inhibitors (TKIs) are the standard of care for resectable and
metastatic non-small-cell lung cancer (NSCLC) harbouring epidermal growth factor receptor …

Background: Lung cancer is a leading cause of cancer-related death in Germany and
worldwide. Non-small cell lung cancer (NSCLC) comprises~ 80% of lung cancer diagnoses; …

Oncogenic mutations within the EGFR kinase domain are well-established driver mutations
in non–small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) …

Background The epidermal growth factor receptor (EGFR)-K745_E746insIPVAIK and others
with XPVAIK amino-acid insertions are exon 19 insertion mutations, which, at the structural …

Adenocarcinoma (ADC) of the lung is the most frequent pathology corresponding to non-
small cell lung cancer (NSCLC). The advent of target therapy and the discovery of drugs that …

Lung cancer is the leading cause of malignancy-related death in the United States and the
second most common cancer diagnosis worldwide. In the last two decades, lung cancer …